Femme et Homme
- | Pays :
- Japan
- Austria
- Slovakia
- Les 5 autres...
- | Organes : -
- | Spécialités : -
Extrait
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
Critère d'inclusion
- Plaque-type Psoriasis